Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8477 randomized withdrawal study in peripheral neuropathic pain
2013-002521-27Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP8477 in Peripheral neuropathic pain, postherpetic neuralgia (PHN) and diabetic polyneuropathy (DPN) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Change in mean 24-hour average pain intensity. Started Oct 2013; status: completed.
02
Drugs
ASP8477
03
Conditions
Peripheral neuropathic painpostherpetic neuralgia (PHN)diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2013-002521-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002521-27.